To assess the potential of amplified MYC family genes as therapeutic target in SCLC, we investigated the effects of Omomyc on MYC inhibition in a panel of SCLC cell lines carrying genetic inactivation of TP53 and RB1, as well as amplification of one of the MYC family genes. The gene discussed is MYC; the disease is small cell lung carcinoma.